HGS Follows Its Single-Cytokine BLISS In Lupus
This article was originally published in The Pink Sheet Daily
Executive Summary
Company bets BLyS specificity will beat ZymoGenetics’ dual approach in Phase III.
You may also be interested in...
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus
NDA could be submitted this year, company says.